TriNav FLX features enhanced trackability and significantly expands the company’s existing TriNav portfolio of products. It offers interventional radiologists more options to select the right product for the right patient, TriSalus said in a news release.
According to TriSalus, the TriNav FLX infusion system retains its existing Pressure-Enabled Drug Delivery (PEDD) benefits. However, it introduces an important advancement in its design. The new system features twice the length of more flexible material at the distal end. This allows for easier navigation through more tortuous vessels.
The company says its enhancement proves particularly beneficial for procedures that require precise control and flexibility due to challenging peripheral vascular anatomy.
TriSalus said its system’s more flexible distal end provides improved navigation through challenging pathways. Additionally, in benchtop models, it demonstrated a 28% reduction in force during navigation compared to the standard TriNav design.
“We’re excited to further expand our TriNav portfolio with the introduction of the TriNav FLX Infusion System,” said Mary Szela, CEO of TriSalus Life Sciences. “With TriNav FLX, we now offer a comprehensive suite of advanced technologies designed to support Interventional Radiologists in navigating a wide range of peripheral vessel sizes and complexities. Our continued investment in portfolio innovation underscores our commitment to making Pressure-Enabled Drug Delivery accessible to more patients. Importantly, TriNav FLX is also eligible for reimbursement under HCPCS Code C8004 for simulation—or mapping—as well as C9797 for treatment procedures. This dual coverage allows clinicians to use TriNav FLX for both planning and delivery in radioembolization, supporting greater precision and continuity of care.”
